Oncologists remained the most restrictive specialists when it comes to meeting with pharmaceutical sales representatives, according to a report by the market research firm ZS Associates. Moderate-to-severe restrictions on drug reps' visits were in place for 65% of oncologists. The comparable figures were 47% for primary care physicians and 58% for cardiologists. Reasons may be because more physicians belong to institutions with restrictive policies, and the number of oncology reps is growing as more drugmakers are concentrating on cancer treatments, ZS Associates' Ganesh Vedarajan said in a statement.

Full Story:

Related Summaries